[{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Menlo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Merger","leadProduct":"Serlopitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Foamix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Foamix Pharmaceuticals \/ Menlo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Foamix Pharmaceuticals \/ Menlo Therapeutics"},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Serlopitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Menlo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menlo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Menlo Therapeutics \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Serlopitant

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Study MTI-105 and Study MTI-106 did not meet their respective primary endpoint of demonstrating statistically significant reduction in pruritus in patients treated with serlopitant.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 06, 2020

                          Lead Product(s) : Serlopitant

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The combined company already has an approved, commercial-stage product, AMZEEQ™, and several late-stage product candidates.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          March 09, 2020

                          Lead Product(s) : Serlopitant

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Menlo Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Serlopitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pruritus.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 15, 2019

                          Lead Product(s) : Serlopitant

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Stanford University

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Stanford University

                          Country arrow
                          The MedTech Conference
                          Not Confirmed

                          Details : Serlopitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Epidermolysis Bullosa.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 11, 2019

                          Lead Product(s) : Serlopitant

                          Therapeutic Area : Rare Diseases and Disorders

                          Highest Development Status : Phase II

                          Sponsor : Epidermolysis Bullosa Research Partnership | VYNE Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Serlopitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pruritus.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 19, 2018

                          Lead Product(s) : Serlopitant

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Serlopitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pruritus.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 06, 2018

                          Lead Product(s) : Serlopitant

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Serlopitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pruritus.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 30, 2018

                          Lead Product(s) : Serlopitant

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Serlopitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pruritus.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 17, 2017

                          Lead Product(s) : Serlopitant

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Serlopitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Chronic Cough.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 14, 2017

                          Lead Product(s) : Serlopitant

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Serlopitant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pruritus.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 29, 2016

                          Lead Product(s) : Serlopitant

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank